More Vaccine Success Overshadowed by Biden Task Force

 

For the second Monday since the election there is encouraging vaccine news. The latest news comes from Moderna, which announced 95% success with its vaccine trials. The stock market responded with another great day.

The Moderna vaccine, like the one from Pfizer, is an mRNA vaccine. They reported 95 people in the study contracted the virus and 90 of those had received the placebo. These findings come from a 30,000 subject trial and moves the company closer to distribution of the vaccine. They only have to complete the safety data, which has been good thus far, at the end of this month.

Like the Pfizer vaccine, the Moderna vaccine requires two shots, approximately three weeks apart. Unlike the Pfizer vaccine, Moderna’s does not require refrigeration at extremely cold temperatures. They estimate, after thawing, it can remain stable in regular refrigerators for up to 30 days. This would greatly simplify distribution of the vaccine compared to the Pfizer vaccine.

You might expect this news to be greeted with enthusiasm by everyone. But there seem to be critics for every situation, no matter how much everyone benefits. Many have criticized the FDA for granting Emergency Use Authorization (EUA) this past summer for convalescent plasma to treat Covid. The Wall Street Journal reports more than a dozen studies showed benefits for this treatment. A Mayo Clinic trial that enrolled some 35,000 patients found seven-day mortality was 44% lower among non-intubated patients under the age of 80 who were treated within 72 hours of diagnosis with plasma containing high levels of antibodies versus lower levels.

These same critics claim the FDA jumped the gun by approving remdesivir and should have waited for supposedly more robust evidence of success. Some say the FDA should have consulted outside experts before granting EUA. By ignoring such naysayers, the Trump Administration has made possible effective treatments and new vaccines in record-breaking time.

The Wall Street Journal editorial board says, “Credit here goes to private drug investment and innovation, but also to the Trump administration for speeding up government approvals. The Administration pushed reforms in the Food and Drug Administration’s bureaucratic and risk-averse culture, even if it didn’t always succeed. Former FDA Commissioner Scott Gottlieb put a particular priority on speeding up drug approvals. New generic approvals increased to 107 last year from 73 in 2016.”

Unfortunately, some of these same critics now make up the Biden Covid task force. Ezekiel Emanuel, one of the notorious architects of the ObamaCare train wreck, was most noted for his creation of an Independent Payment Advisory Board (IPAB) which was designed to control Medicare spending. Thankfully, the IPAB has since been repealed by Congress. But Emanuel continues to be favored by Democrats who are more concerned with spending than taking care of people. He believes government needs to clamp down on doctors who prescribe treatments that incrementally help patients, especially the elderly with fewer years to live. In other words, he favors rationing of healthcare, like socialized medicine.

Another Biden Covid task force member is David Kessler, FDA commissioner under George H.W. Bush and Bill Clinton. The WSJ says Kessler let the agency be hijacked by trial lawyers and banned most silicone breast implants because of unascertainable risks, which many women were willing to bear. During his tenure, approvals of new medical devices ground to a halt. Kessler told Politico in August, “The FDA commissioner is to put their body on the line in between all the forces that want to influence the agency.” The WSJ says he meant the agency should ignore doctors and patients who want access to therapies that don’t pass this “expert” bureaucratic obstacle course.

The election results show many Americans voted for Biden believing he would do a better job than Trump on handling the Covid pandemic. Yet the Biden plan differed little from the Trump plan except for a national mask-wearing mandate. (Biden’s Covid Plan is Trump’s Plan)

But now it appears Biden may actually contribute to a worsening of the pandemic crisis. The WSJ editorial board summarizes their concerns: “The Trump FDA’s Covid innovation has been providing real-time feedback and clear guidance to drug and vaccine makers about its expectations. This has helped therapies and vaccines advance and cut Phase 3 trials from three years to three months. These reforms are one of the success stories of the federal Covid response. But there’s a serious risk that the Biden team will default to their instincts and reimpose a culture of bureaucratic control that restricts new medical advances.”

It’s easy to be a critic when you’re not in charge.

What Biden Healthcare Might Look Like – Part II

 

In Part I of this series, we discussed what changes a President Biden might make in our healthcare system. Insurance industry analyst, Robert Laszewski, has described the Biden plan in three parts:

  • Creating a government-run individual health insurance plan called the Public Option
  • Fixing the ObamaCare individual health insurance subsidies for the middle class
  • Giving Medicare the power to negotiate prescription drug prices

 

In Part I, I discussed the Public Option. Today we’ll cover the next two parts of the Biden plan.

Fixing ObamaCare Middle Class Subsidies

The current ObamaCare exchange subsidies are provided for those families who earn up to 400% of the Federal Poverty Level (FPL). Those who earn no more than 138% of FPL qualify for Medicaid, if their state accepted the terms of the Medicaid expansion under ObamaCare. Therefore, if you earn more than 138% FPL and less than 400% FPL, you get a income-graded subsidy to purchase your individual health insurance plan on the Obamacare exchanges. (see the FPL graphic below)

Laszewski says Biden will increase the subsidies for the middle class, by ending the income cut-off that currently exists at 400% of FPL. He will extend the subsidies to any family whose insurance costs exceed 8.5% of their income. He would also significantly increase the premium subsidy by tying subsidies to what it takes to buy the generous Gold Plan, instead of the current rule that ties the subsidy to the standard Silver Plan.

It is true that the middle class has been the biggest loser in the ObamaCare system. They must bear the largest brunt of the ever-rising insurance premiums with the lowest income to pay for them. They often face annual family premiums in the $15,000 to $20,000 range with deductibles in the $7,000 area. Laszewski says under Biden’s fixes, a family making $150,000 would pay no more than $12,750 in annual premiums with much reduced deductibles.

Laszewski believes this idea could garner enough Republican support to pass through the Senate even if Republicans control the Senate. The larger issue will be finding a way to pay for this. Biden has already announced tax hikes on those earning more than $400,000 a year. He would also tax capital gains at ordinary rates for people earning more than $1 million a year and eliminate the step-up basis for the sale of securities by heirs. But if he wants to further the progressive agenda of free college tuition, the Green New Deal, and free healthcare for illegal immigrants, he will need much more tax revenue than that.

Prescription Drug Prices

Biden wants to reduce prescription drug prices by making a government-negotiated drug price available to Medicare, his Public Option, and to private individual and employer plans that wanted to take advantage of it. He would also set up an independent board to establish prices for new breakthrough drugs not subject to competition and enable drugs to be imported from countries that have already negotiated the lowest prices, as well as cap annual drug price increases at the rate of inflation.

Laszewski says there is no chance of these changes with a Republican-controlled Senate. They oppose government price controls which will hamper the development of new critically-needed drugs such as the Covid-19 therapeutics and vaccines.

There is support for changes to Medicare by adding an out-of-pocket maximum for beneficiaries and capping drug-price increases at the rate of inflation. A bipartisan bill in the Senate currently is sponsored by Republican Chuck Grassley (IA) and Democrat Ron Wyden (OR). This is a more likely scenario for improvement in drug prices.

ObamaCare Regulations

President Trump made some changes in ObamaCare regulations to lower the cost of premiums through short-term limited benefit plans (STLB) that do not have to conform to all the ObamaCare regulations. Democrats call these “junk insurance” plans but they simply avoid expensive provisions of the regular ObamaCare plans that these individuals do not need. These regulations are the main drivers of the high-cost of ObamaCare plan premiums.

The Biden administration may kill these plans, but they would dump two million or more Americans into the ranks of the uninsured if they do. Biden may also try to expand Medicaid to more states, but has not provided details of any changes he might make to achieve this goal.

The Democratic goal of socialized medicine is closer than ever, but there is still a long way to go before they can achieve that prize. The biggest hurdle they must overcome now is a Republican-controlled Senate.

What Biden Healthcare Might Look Like – Part I

 

Now that Joe Biden appears to have won the election, what will he do to our healthcare? Unless Republican legal challenges of the vote counting alter the result, Biden will be in charge of our healthcare. That’s a big question on the minds of many Americans.

The Democratic left wants socialized medicine. Senator Bernie Sanders, the ideological leader of the party (even though he’s an Independent!) has pushed for Medicare for All, a complete government takeover of healthcare. New Vice President-elect Kamala Harris supports Medicare for All, or at least she did when she was running for president. Biden never endorsed their plan, but he is willing to add a Public Option to ObamaCare. What will all that mean?

Robert Laszewski, noted insurance industry analyst, has much to say on this subject in his healthcare blog. Today I’ll begin a two-part post that discusses Laszewski’s predictions and my reactions.

Laszewski says the Biden healthcare plan is in three parts:

  • Creating a government-run individual health insurance plan called the Public Option
  • Fixing the ObamaCare individual health insurance subsidies for the middle class
  • Giving Medicare the power to negotiate prescription drug prices

 

The Public Option

Let’s take the most controversial part first, the Public Option. The Public Option would be a new government-run plan that would compete with current private plans on the ObamaCare Exchange. Individuals who do not receive employer-provided insurance would be offered this Public Option along with the private plans currently available. These plans generally pay hospitals 40% less and doctors 20% less than employer-provided insurance.

Laszewski says employers worry that giving their employees access to a cheaper government plan will undermine their own benefits and ultimately back them into government health insurance whose costs they will not have control over. Insurance companies will worry a cheaper government option driven by Medicare-like reimbursement rates in the insurance exchanges will drive out commercial plans starting in the individual market and spreading to the employer market.

Healthcare providers (doctors and hospitals) will worry that introducing another government plan that pays hospitals 40% less, and doctors 20% less, will squeeze their ability to operate even more than the pressure they already feel from Medicare and Medicaid. Patients should worry that their private insurance plans will be eventually eliminated by the competition from the Public Option.

In other words, hospitals and doctors barely get by when they have to accept Medicare, Medicaid, and exchange individual plans. They make up for these low-paying customers with higher reimbursements from employer-provided insurance. If the employer-provided insurance plans have to compete with these government-subsidized plans more, the whole system of providers will be stretched to cover their costs. The eventual elimination of private insurers will mean doctors will be forced to accept lower-paying government plans.

This will create a defacto socialized medicine system, where providers’ fees are controlled by the government. As in all socialized medicine systems, this will lead to diminished access to healthcare as many doctors retire early or leave the clinical practice of medicine. Those who remain will not be incentivized to see more patients so waiting times will increase and services will be limited.

Laszewski believes that even the Democrats in Congress will reject such a radical change in our system and will not pass the Public Option. It is true this idea was rejected in 2010 during the Obama administration development of ObamaCare, but progressives have a far stronger position in the party now than they did then.

I’m less optimistic than Laszewski. The progressive Democrats have been itching for socialized medicine for the last hundred years. ObamaCare moved them closer to that goal, but they haven’t taken their eyes off the prize. The Public Option is the next step to achieve their goal and there will be great pressure on Biden and Congressional Democrats to move forward. The best defense against such radical change is a Republican-controlled Senate.